BioLife Solutions Joins S&P SmallCap 600 Index
-BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 124 companies hit new 52-week highs.
Keybanc Maintains Overweight on BioLife Solutions, Raises Price Target to $60
Keybanc analyst Paul Knight maintains BioLife Solutions (NASDAQ:BLFS) with a Overweight and raises the price target from $50 to $60.
Recap: BioLife Solutions Q2 Earnings
Shares of BioLife Solutions (NASDAQ:BLFS) moved higher by 4.2% in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 100.00% over the past year to ($0.00), which beat the estimate of ($0.07).
BioLife Solutions Q2 Adj. EPS $0.00 Beats $(0.07) Est., Sales $31.20M Beat $27.55M Estimate
BioLife Solutions (NASDAQ:BLFS) reported quarterly sales of $31.20 million which beat the analyst consensus estimate of $27.55 million by 13.25 percent. This is a 214.52 percent increase over sales of $9.92 million the
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell
• Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)